复星医药子公司复宏汉霖与Sandoz AG签订协议,授权其在多个国家和地区开发、生产及商业化在研产品HLX13,用于治疗多种癌症。HLX13在中国处于I期临床研究阶段。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.